Form 4: TriSalus Life Sciences Director Mats Wahlstrom Granted 15,000 Stock Options

TriSalus Life Sciences, Inc. Director Mats Wahlstrom was granted 15,000 stock options with an exercise price of $5.50, vesting over one year or upon the next annual stockholder meeting.

Summary

• Mats Wahlstrom, a Director of TriSalus Life Sciences, Inc. (TLSI), was granted 15,000 Director Stock Options.
• The options have an exercise price of $5.50 per share.
• The grant date for these options was June 12, 2025.
• The options will fully vest on the one-year anniversary of the grant date (June 12, 2026), or in any case, on the date of the Issuer's next annual stockholder meeting, subject to Mr. Wahlstrom's continued service.
• The options have an expiration date of June 11, 2035.
• Following this transaction, Mr. Wahlstrom beneficially owns 200,945 derivative securities.

Sentiment

Score: 6

Explanation: Slightly positive, as the grant of stock options to a director generally indicates alignment of interests and incentivizes long-term performance, which is a positive for shareholders.

Positives

• The grant of stock options to a director aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The options were granted at an exercise price of $5.50, providing a clear target for value creation.

Risks

• The vesting of the stock options is contingent upon the Reporting Person's continued service with the Issuer, meaning the options could be forfeited if service ceases before vesting.

Future Outlook

The stock options granted to Director Mats Wahlstrom are set to fully vest on the one-year anniversary of the grant date (June 12, 2026) or, at the latest, on the date of the Issuer's next annual stockholder meeting, contingent on his continued service.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries, particularly in publicly traded companies where equity compensation is a standard practice for attracting and retaining key personnel and aligning their interests with shareholders.

Corporate Governance

Related Party Transactions

• The grant of stock options to a director constitutes a related party transaction, as it involves compensation provided to an insider of the company.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of director's interests with shareholder value.
• Director (Mats Wahlstrom): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance and continued service.

Next Steps

• The stock options will vest on the one-year anniversary of the grant date (June 12, 2026) or at the Issuer's next annual stockholder meeting, subject to continued service.

Key Dates

Keywords

TriSalus Life Sciences, TLSI, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Corporate Governance